NLS Pharmaceutics AG Secures CHF27M to Accelerate Innovative Brain Therapeutics

NLS Pharmaceutics AG is thrilled to announce that we have successfully raised 27,000,000 to further advance our mission of designing affordable, safe, and effective therapeutics that safeguard and empower the brain throughout all stages of life. This significant funding milestone is a testament to our unwavering commitment to ethical innovation and underscores our leadership in the fields of psychiatry and neurology. At NLS Pharmaceutics, we have always believed that the successful companies of tomorrow will be those that go beyond delivering products to providing holistic solutions and services that meet real patient needs. With this new investment, we will accelerate our robust R&D efforts, deepening our focus on addressing underdiagnosed and challenging conditions such as attentional disorders, excessive daytime sleepiness, pervasive developmental disorders, cognitive impairments, and synucleopathies. The funds will be strategically allocated to bolster our innovative research programs and to further refine our intellectual property strategy, ensuring that more targeted and cost-effective treatments are within reach. By streamlining our pipeline and enhancing collaborations with key partners, we aim to deliver breakthroughs in cognitive and attentional enhancement as well as advanced neurological therapies. Our promise to uphold our core values of partnership, integrity, respect, and compassion remains the driving force behind every decision we make. Although we are not currently hiring, we continue to invest in groundbreaking research that not only improves access to quality healthcare but also meets the unmet needs of patients worldwide, laying the foundation for sustainable growth and long-term success in our mission to transform patient care.